Share on LinkedInShare on LinkedIn

ARTICLE · 29 NOVEMBER 2020

What's Next For U.S. Biosimilar Litigation

Herbert Smith Freehills Kramer LLP
Herbert Smith Freehills Kramer LLP
Contributor
Herbert Smith Freehills Kramer LLP

Herbert Smith Freehills Kramer LLP

We have one of the largest Southeast Asia international law practices, working across the region...

View firm profile
Explore more from Herbert Smith Freehills Kramer LLP

Intellectual Property partner Irena Royzman and associate Michael A. Anderson authored a Bloomberg Law article titled "What's Next for U.S. Biosimilar Litigation" on Nov. 20, 2020

United StatesIntellectual Property

Kramer Levin Naftalis & Frankel LLP attorneys discuss the direction of biosimilar litigation from recent federal court rulings. They also look at trends in patent litigation and what to expect in 2021 and beyond.

The Biologics Price Competition and Innovation Act (BPCIA) turned 10 this year, making it a good time to look at recent litigation trends and assess what's ahead for 2021.

U.S. biosimilar litigation continues to take shape, although most cases have resolved without a decision on the merits. The U.S. Court of Appeals for the Federal Circuit has provided guidance on the requirements for the BPCIA's 180-day notice of commercial marketing and biosimilar injunctions.

Manufacturing patents protecting all aspects of the manufacture of biologics continue to play a central role in biosimilar litigation, as biosimilar makers are obtaining patents to protect their products and gain a competitive edge.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from